Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6324

Provisional Schedule

Committee meeting 14 May 2025
Expected publication 23 July 2025

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors Roche (atezolizumab)
  Association of Cancer Physicians
  British Thoracic Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Others Department of Health and Social Care
  NHS England
Patient carer groups None
Associated public health groups None
Comparator companies AstraZeneca (osimertinib) - confidentiality agreement signed, participating
  Merck Sharp and Dohme (pembrolizumab) -confidentiality agreement signed, participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
02 October 2024 Invitation to participate
21 August 2024 - 05 September 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
21 August 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
21 August 2024 In progress. Draft scope issued

For further information on our processes and methods, please see our CHTE processes and methods manual